Significant association between CD44 polymorphism rs13347 and cancer susceptibility was observed under all genetic models (Fig. 1): allele contrast (T vs. C, OR = 1.391, 95% CI = 1.172–1.650, P < 0.001); dominant model (TT+CT vs. CC, OR = 1.462, 95% CI = 1.176–1.818, P = 0.001); recessive model (TT vs. CT+CC, OR = 1.810, 95% CI = 1.440–2.275, P < 0.001); homozygous model (TT vs. CC, OR = 2.122, 95% CI = 1.576–2.857, P < 0.001); and heterozygous model (CT vs. CC, OR = 1.389, 95% CI = 1.133–1.702, P = 0.002). This evidence concerns the gene CD44 and cancer.